We explored whether stem cell therapy was effective for animal models and patients with Crohn’s disease (CD). We searched five online databases. The relative outcomes were analyzed with the aid of GetData Graph Digitizer 2.26 and Stata 16.0 software. The SYRCLE risk of bias tool and the MINORS tool were used to assess study quality. We evaluated 46 studies including 28 animal works (n = 567) and 18 human trials (n = 360). In the animal studies, the disease activity index dramatically decreased in the mesenchymal stem cell (MSC) treatment groups compared to the control group. Rats and mice receiving MSCs exhibited longer colons [mice: standardized mean difference (SMD) 2.84, P = 0.000; rats: SMD 1.44, P = 0.029], lower histopathological scores (mice: SMD − 4.58, p = 0.000; rats: SMD − 1.41, P = 0.000) and lower myeloperoxidase levels (SMD − 6.22, P = 0.000). In clinical trials, stem cell transplantation reduced the CD activity index (SMD − 2.10, P = 0.000), the CD endoscopic index of severity (SMD − 3.40, P = 0.000) and simplified endoscopy score for CD (SMD − 1.71, P = 0.000) and improved the inflammatory bowel disease questionnaire score (SMD 1.33, P = 0.305) compared to control values. CD patients maintained high remission rates for 3–24 months after transplantation. Stem cell transplantation is a valuable supplementary therapy for CD.

中文翻译：

---

克罗恩病的干细胞治疗：临床前和临床研究的系统评价和荟萃分析

我们探讨了干细胞疗法对动物模型和克罗恩病 (CD) 患者是否有效。我们搜索了五个在线数据库。借助 GetData Graph Digitizer 2.26 和 Stata 16.0 软件分析相关结果。SYRCLE 偏倚风险工具和 MINORS 工具用于评估研究质量。我们评估了 46 项研究，包括 28 项动物作品（n = 567）和 18 项人体试验（n = 360）。在动物研究中，与对照组相比，间充质干细胞 (MSC) 治疗组的疾病活动指数显着降低。接受 MSCs 的大鼠和小鼠表现出更长的结肠 [小鼠：标准化平均差 (SMD) 2.84，P = 0.000；大鼠：SMD 1.44，P = 0.029]，较低的组织病理学评分（小鼠：SMD - 4.58，p = 0.000；大鼠：SMD - 1.41，P = 0.000）和较低的髓过氧化物酶水平（SMD - 6.22，P = 0.000）。在临床试验中，干细胞移植降低了 CD 活动指数（SMD − 2.10，P = 0.000）、CD 内窥镜严重程度指数（SMD − 3.40，P = 0.000）和简化的 CD 内窥镜评分（SMD − 1.71，P = 0.000）并与对照值相比提高了炎症性肠病问卷评分（SMD 1.33，P = 0.305）。CD 患者在移植后 3-24 个月内保持高缓解率。干细胞移植是一种有价值的 CD 补充疗法。CD 患者在移植后 3-24 个月内保持高缓解率。干细胞移植是一种有价值的 CD 补充疗法。CD 患者在移植后 3-24 个月内保持高缓解率。干细胞移植是一种有价值的 CD 补充疗法。